{"id":20241,"date":"2024-08-22T11:06:44","date_gmt":"2024-08-22T15:06:44","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=private_project&#038;p=20241"},"modified":"2025-02-28T08:50:27","modified_gmt":"2025-02-28T13:50:27","slug":"exploring-the-real-world-use-of-atezolizumab-in-ontario-canada","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/","title":{"rendered":"Exploring the real-world use of atezolizumab in Ontario, Canada"},"content":{"rendered":"<p><strong>Client:<\/strong> Hoffmann-La Roche Limited<\/p>\n<p><strong>Project ID:<\/strong> P2023-204\/ 2025 0970 391 000<\/p>\n<p><strong>Research Question\/Objectives:<\/strong> Tecentriq (atezolizumab) is a type of cancer immunotherapy treatment with a number of approved indications in Canada, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). To understand the real-world use of atezolizumab\u2014and determine the feasibility of conducting further RWD studies in the respective disease area cohorts\u2013we sought to explore and extrapolate from the RWD available for the province of Ontario.<\/p>\n<p><strong>Objectives:<\/strong><\/p>\n<p>Primary Objective:<\/p>\n<ul>\n<li>To characterize the frequency and percentage of atezolizumab use, by indication and by month\/year; and, where possible, broken down by:\n<ul>\n<li>Local Health Integration Network (LHIN)<\/li>\n<li>New starts<\/li>\n<li>Cumulative usage<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Secondary Objectives:<\/p>\n<ul>\n<li>To describe the group of atezolizumab-treated HCC patients by:\n<ul>\n<li>Whether they received an upper endoscopy (esophagogastroduodenoscopy or EGD) anytime after diagnosis (%)<\/li>\n<li>Duration of Tx (months between first and last atezolizumab)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Status:<\/strong> Completed<\/p>\n<p><strong>Results:<\/strong> August 2025<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Client: Hoffmann-La Roche Limited Project ID: P2023-204\/ 2025 0970 391 000 Research Question\/Objectives: Tecentriq (atezolizumab) is a type of cancer immunotherapy treatment with a number of approved indications in Canada, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). To understand the real-world use of atezolizumab\u2014and determine the feasibility [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-20241","private_project","type-private_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":"P2023-204\/ 2025 0970 391 000","project_id_year":2024,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exploring the real-world use of atezolizumab in Ontario, Canada | ICES<\/title>\n<meta name=\"description\" content=\"Client: Hoffmann-La Roche Limited Project ID: P2023-204\/ 2025 0970 391 000 Research Question\/Objectives: Tecentriq (atezolizumab) is a type of cancer\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring the real-world use of atezolizumab in Ontario, Canada | ICES\" \/>\n<meta property=\"og:description\" content=\"Client: Hoffmann-La Roche Limited Project ID: P2023-204\/ 2025 0970 391 000 Research Question\/Objectives: Tecentriq (atezolizumab) is a type of cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-28T13:50:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\\\/\",\"name\":\"Exploring the real-world use of atezolizumab in Ontario, Canada | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2024-08-22T15:06:44+00:00\",\"dateModified\":\"2025-02-28T13:50:27+00:00\",\"description\":\"Client: Hoffmann-La Roche Limited Project ID: P2023-204\\\/ 2025 0970 391 000 Research Question\\\/Objectives: Tecentriq (atezolizumab) is a type of cancer\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Private Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Exploring the real-world use of atezolizumab in Ontario, Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exploring the real-world use of atezolizumab in Ontario, Canada | ICES","description":"Client: Hoffmann-La Roche Limited Project ID: P2023-204\/ 2025 0970 391 000 Research Question\/Objectives: Tecentriq (atezolizumab) is a type of cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/","og_locale":"fr_FR","og_type":"article","og_title":"Exploring the real-world use of atezolizumab in Ontario, Canada | ICES","og_description":"Client: Hoffmann-La Roche Limited Project ID: P2023-204\/ 2025 0970 391 000 Research Question\/Objectives: Tecentriq (atezolizumab) is a type of cancer","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-02-28T13:50:27+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/","name":"Exploring the real-world use of atezolizumab in Ontario, Canada | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2024-08-22T15:06:44+00:00","dateModified":"2025-02-28T13:50:27+00:00","description":"Client: Hoffmann-La Roche Limited Project ID: P2023-204\/ 2025 0970 391 000 Research Question\/Objectives: Tecentriq (atezolizumab) is a type of cancer","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/exploring-the-real-world-use-of-atezolizumab-in-ontario-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Private Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Exploring the real-world use of atezolizumab in Ontario, Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project\/20241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/private_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=20241"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=20241"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=20241"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=20241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}